25 results on '"Lee, Byung Ha"'
Search Results
2. An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
3. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
4. Systematic Assessment of the Positive Role of Arabidopsis thaliana GROWTH-REGULATING FACTORs in Regulation of Cell Proliferation During Leaf Growth
5. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions
6. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
7. Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.
8. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8+T and CAR-T cells
9. CTIM-33. EFFICACY AND SAFETY STUDY OF NEOADJUVANT EFINEPTAKIN ALFA (NT-I7) AND PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA
10. EXTH-52. LONG-ACTING RECOMBINANT INTERLEUKIN-7, NT-I7, IMPROVES SURVIVAL FOLLOWING ONCOLYTIC ZIKA VIRUS TREATMENT IN THE SB28 IMMUNOSUPPRESSIVE AND TREATMENT-RESISTANT MURINE GLIOMA MODEL
11. 652 NT-I7 (efineptakin alfa), a long-acting IL-7, in combination with pembrolizumab improves T cell fitness in heavily pretreated subjects with gastrointestinal tumors
12. Abstract 6786: NT-I7 as an adjuvant to DNA neoantigen vaccination enhances and prolongs neoantigen-specific anti-tumor immunity
13. Supplementary Figure from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models
14. Supplementary Data from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models
15. A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma
16. 657 NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer
17. 849 NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model
18. 679 NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: a clinical trial in progress
19. The Role of Interleukin-7 in the Formation of Tertiary Lymphoid Structures and Their Prognostic Value in Gastrointestinal Cancers
20. A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
21. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models
22. Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy
23. An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies
24. Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
25. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.